Irritable bowel syndrome, constipation predominant IBS-c Irritable bowel syndrome, diarrhoea predominant IBS-d IBS-m Irritable bowel syndrome, mixed diarrhoea and constipation symptoms IBS-u Irritable bowel syndrome, unspecified ICH International Conference on Harmonisation IP Intraperitoneal Intravenous/intravenously IV Key Opinion Leader KOL KOR Kappa-opioid receptor/k-opioid receptor LD Lactation Day Liver function test LFT limit of quantification LLOQ M1 Muscarinic 1 receptor M2 Eluxadoline metabolite Medical Dictionary for Regulatory Affairs MedDRA Mu-opioid receptor/μ-opioid receptor MOR MRHD Maximum recommended human dose N Number N-methyl-D-aspartate receptor NMDA No observable adverse effect level NOAEL OR Opioid receptor PI Product Information Paediatric Investigation Plan PIP Orally (Latin: per os) PO PSUR Periodic Safety Update Report RMP Risk Management Plan
IBS-c Irritable bowel syndrome, constipation predominant IBS-d Irritable bowel syndrome, diarrhoea predominant IBS-m Irritable bowel syndrome, mixed diarrhoea and constipation symptoms IBS-u Irritable bowel syndrome, unspecified ICH International Conference on Harmonisation IP Intraperitoneal IV Intravenous/intravenously KOL Key Opinion Leader KOR Kappa-opioid receptor/k-opioid receptor LD Lactation Day LFT Liver function test LLOQ limit of quantification M1 Muscarinic 1 receptor M2 Eluxadoline metabolite MedDRA Medical Dictionary for Regulatory Affairs MOR Mu-opioid receptor/μ-opioid receptor MRHD Maximum recommended human dose N Number NMDA N-methyl-D-aspartate receptor NOAEL No observable adverse effect level OR Opioid receptor PI Product Information PIP Paediatric Investigation Plan PO Orally (Latin: per os) PSUR Periodic Safety Update Report RMP Risk Management Plan